PaulMaurin

Collaborateur

Paris + 33.1.56.59.39.13

Paul Maurin intervient sur les aspects français et internationaux des dossiers de capital risque, private equity, fusions-acquisitions et droit boursier du Cabinet.

Il conseille régulièrement des sociétés cotées ou non et leurs dirigeants aux différents stades de leur développement ainsi que leurs investisseurs (acteurs du capital risque et du private equity, investisseurs institutionnels et industriels). Il représente les émetteurs comme les investisseurs lors de tours de financement, d'opérations de fusion-acquisition publiques ou privées, de LBO, dans le cadre d'introductions en bourse, de placements privés ou encore d'offres publiques.

A ce titre, Paul Maurin a récemment conseillé des entreprises technologiques et des sociétés du secteur des sciences de la vie (Stratumn, Voluntis, Nanobiotix), ainsi que des investisseurs, tels que Partech Partners, Bpifrance, Creadev (famille Mulliez), Piton Capital LLP et Alven Capital Partners.

Parmi les transactions représentatives de son expérience figurent l'acquisition par Ansys d'Optis, la vente d'A2Mac1 par ses fondateurs, le financement de Doctolib, ManoMano, Tinubu Square, les introductions en bourse de Voluntis et Tikehau, les placements privés de Nanobiotix et Cellnovo et l'augmentation de capital de Voltalia.

Expérience

  • Nanobiotix completes $113.3 million IPO on NasdaqJones Day represented Nanobiotix S.A., a French clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, in connection with its $113.3 million initial public offering in the United States and listing on Nasdaq.
  • Tinubu® Square acquires U.S. company eSURETY®Jones Day advised Tinubu® Square in its acquisition of U.S.-based eSURETY®, a cloud-based specialty software provider, enabling carriers, brokers, and MGAs to securely apply, quote, bond, issue, and support every form of surety as well as offering a powerful direct-to-the-consumer experience on any device from any browser, anywhere in the world.
  • Voltalia completes €376 million capital increase with shareholders’ preferential subscription rightsJones Day represented Voltalia S.A. in connection with its €376 million offering by way of preferential subscription rights allocated to Voltalia's existing shareholders in a public offering in France and internationally in private placements to institutional investors.
  • Gimv invests in Coolworld RentalsJones Day advised Gimv in its acquisition of a majority shareholding in fast-growing Coolworld Rentals, a full-service renter of cooling and heating equipment.
  • Bain Capital Ventures participates in $70 million Series C financing round of MiraklJones Day represented Bain Capital Ventures in connection with the $70 million Series C round of financing of Mirakl, a global leader in e-commerce marketplace platforms.
  • Findos Investor acquires worldwide business of Röder HTS Höcker GmbHJones Day advised funds managed by Findos Investor in connection with acquisition of the entire worldwide business operations of Röder HTS Höcker GmbH.
  • Athyrium Capital Management partially issues second tranche of bond issueJones Day advised Athyrium Capital Management, LP in connection with the partial issuance of the second tranche of its bond issue.
  • Bpifrance and Danone Manifesto Ventures participate in €25 million Series B financing round of AgricoolJones Day represented Bpifrance and Danone Manifesto Ventures, as lead investors, in connection with the €25 million (US$28.2 million) Series B financing round of Agricool, a greentech company developing and using containers to grow fruits and vegetables in urban areas.
  • Stilla Technologies raises €16 million in Series A roundJones Day represented Stilla Technologies SAS, the European provider of pioneering digital PCR solutions for high precision genetic analysis, in connection with its issuance of €16 million (US$18 million) of Series A Convertible Preferred Stock in a private placement to Illumina Ventures, Kurma Partners, LBO France, BNP Paribas Développement, Paris Saclay Seeds, and Idinvest Partners.
  • Deezer enters into exclusive distribution agreement with Rotana, leading media group in Middle EastJones Day is assisting Deezer, a leader in music streaming, in the negotiation and execution of an exclusive distribution agreement with Rotana Group, the leading media group in the Middle East, to distribute Rotana's audio and video content catalogue exclusively on Deezer's platform in the Middle East and North Africa regions.
  • Voluntis completes €30.1 million IPO on regulated market of Euronext in ParisJones Day advised Voluntis S.A., a French company specializing in therapeutic software, and Bryan, Garnier & Co and Oddo BHF SCA, joint lead managers and joint bookrunners, in connection with Voluntis' €30.1 million (US$34.9 million) initial public offering on the regulated market of Euronext in Paris.
  • ANSYS acquires OPTISJones Day advised ANSYS, Inc., the global leader and innovator of engineering simulation software, on its acquisition of OPTIS, a premier provider of software for scientific simulation of light, human vision, and physics-based visualization.
  • Bpifrance and Balestier participate in €27 million financing round of LimFlowJones Day represented Bpifrance and Balestier in connection with a €27 million (US$33.5 million) Series C round of financing of LimFlow SA, a developer of innovative, peripheral endovascular technology transforming the treatment of critical limb ischemia.
  • A2Mac1 sold to Five Arrows Principal InvestmentsJones Day advised A2Mac1, a leading player in benchmarking data for the automotive industry, and the selling founders in connection with the leveraged buy-out by Five Arrows Principal Investments.
  • Otium Management invests in OwkinJones Day represented Otium Management in its funds' investments in Owkin, Inc., an artificial intelligence software company currently working on machine learning-based prediction modeling for drug trial optimization, clinical decision-making using population comparison, and other healthcare applications.
  • Nanobiotix completes €27.2 million placement of new sharesJones Day advised Nanobiotix, an oncology focused nanomedicine company listed on the regulated market of Euronext in Paris, in connection with its €27.2 million (US$31.6 million) placement of new shares to U.S. and European investors.
  • Bpifrance invests in Tinubu SquareJones Day represented Bpifrance in connection with its investment in Tinubu Square, a provider of trade credit risk management solutions.
  • BNP Paribas, Citigroup Global Markets, Natixis, and Morgan Stanley complete €702 million rights offering by TikehauJones Day represented BNP Paribas, Citigroup Global Markets Limited, Natixis, and Morgan Stanley in connection with the €702 million rights offering by Tikehau Capital, an asset management and investment group.
  • Cellnovo completes €17.5 million private placement of new sharesJones Day advised Cellnovo, a medical technology company marketing the first mobile, connected, all-in-one diabetes management system, listed on the regulated market of Euronext in Paris, and Oddo BHF in connection with the €17.5 million (US$19.9 million) private placement of Cellnovo new shares to European investors.
  • Onxeo completes €15 million private placement of new sharesJones Day advised Onxeo, a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology and listed on the regulated markets of Euronext in Paris and Nasdaq OMX in Copenhagen, in connection with its €15 million (US$16.7 million) private placement of new shares to U.S. and European investors.
  • *We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.